191 related articles for article (PubMed ID: 16222309)
21. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; Tura S; Baccarani M; Cavo M
Eur J Haematol; 2006 May; 76(5):399-404. PubMed ID: 16480429
[TBL] [Abstract][Full Text] [Related]
22. Optimal management of metastatic bone disease.
Major P
Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
[TBL] [Abstract][Full Text] [Related]
23. Lactate dehydrogenase is a prognostic indicator for prostate cancer patients with bone metastasis.
Naruse K; Yamada Y; Aoki S; Taki T; Nakamura K; Tobiume M; Zennami K; Katsuda R; Sai S; Nishio Y; Inoue Y; Noguchi H; Hondai N
Hinyokika Kiyo; 2007 May; 53(5):287-92. PubMed ID: 17561711
[TBL] [Abstract][Full Text] [Related]
24. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.
Delea T; McKiernan J; Brandman J; Edelsberg J; Sung J; Raut M; Oster G
J Support Oncol; 2006; 4(7):341-7. PubMed ID: 16892696
[TBL] [Abstract][Full Text] [Related]
25. Biochemical approach to the detection and monitoring of metastatic bone disease: What do we know and what questions need answers?
Tankó LB; Karsdal MA; Christiansen C; Leeming DJ
Cancer Metastasis Rev; 2006 Dec; 25(4):659-68. PubMed ID: 17160557
[TBL] [Abstract][Full Text] [Related]
26. [Evaluation of cancer-induced bone diseases by bone metabolic marker].
Takahashi S
Clin Calcium; 2006 Apr; 16(4):581- 90. PubMed ID: 16582508
[TBL] [Abstract][Full Text] [Related]
27. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates.
Berruti A; Dogliotti L; Tucci M; Tarabuzzi R; Fontana D; Angeli A
J Urol; 2001 Dec; 166(6):2023-31. PubMed ID: 11696699
[TBL] [Abstract][Full Text] [Related]
28. Usefulness of alpha1-antichymotrypsin-PSA complex for predicting bone metastases of prostate cancer.
Kikuchi E; Nakashima J; Ishibashi M; Ohigashi T; Oya M; Nakagawa K; Miyajima A; Murai M
Urology; 2006 Aug; 68(2):371-5. PubMed ID: 16904455
[TBL] [Abstract][Full Text] [Related]
29. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
Okegawa T; Kinjo M; Nutahara K; Higashihara E
Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
[TBL] [Abstract][Full Text] [Related]
30. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE.
Ryan CJ; Elkin EP; Small EJ; Duchane J; Carroll P
Urol Oncol; 2006; 24(5):396-402. PubMed ID: 16962488
[TBL] [Abstract][Full Text] [Related]
31. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer.
Smith MR; Cook RJ; Coleman R; Brown J; Lipton A; Major P; Hei YJ; Saad F
Urology; 2007 Aug; 70(2):315-9. PubMed ID: 17826496
[TBL] [Abstract][Full Text] [Related]
32. Bisphosphonate and low-dose dexamethasone treatment for patients with hormone-refractory prostate cancer.
Ueda T; Suzuki H; Akakura K; Ishihara M; Kamiya N; Komiya A; Shimbo M; Suyama T; Sakamoto S; Ichikawa T
Hinyokika Kiyo; 2006 Jul; 52(7):515-21. PubMed ID: 16910582
[TBL] [Abstract][Full Text] [Related]
33. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
Saad F; McKiernan J; Eastham J
Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
[TBL] [Abstract][Full Text] [Related]
34. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
35. Serum thyroid-stimulating hormone is elevated in men with Gleason 8 prostate cancer.
Lehrer S; Diamond EJ; Stone NN; Stock RG
BJU Int; 2005 Aug; 96(3):328-9. PubMed ID: 16042724
[TBL] [Abstract][Full Text] [Related]
36. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer.
Krejcarek SC; Chen MH; Renshaw AA; Loffredo M; Sussman B; D'Amico AV
Urology; 2007 Mar; 69(3):515-9. PubMed ID: 17382156
[TBL] [Abstract][Full Text] [Related]
37. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
[TBL] [Abstract][Full Text] [Related]
38. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.
Selander KS; Brown DA; Sequeiros GB; Hunter M; Desmond R; Parpala T; Risteli J; Breit SN; Jukkola-Vuorinen A
Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):532-7. PubMed ID: 17372249
[TBL] [Abstract][Full Text] [Related]
39. [Role of biochemical indices as metastatic markers in patients with prostatic cancer invading skeleton].
Liubimova NV; Trapeznikova MF; Robins SP; Ognerubov SA; Kushlinskiĭ NE
Urologiia; 2000; (4):15-9. PubMed ID: 11186686
[TBL] [Abstract][Full Text] [Related]
40. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.
Shah RB; Mehra R; Chinnaiyan AM; Shen R; Ghosh D; Zhou M; Macvicar GR; Varambally S; Harwood J; Bismar TA; Kim R; Rubin MA; Pienta KJ
Cancer Res; 2004 Dec; 64(24):9209-16. PubMed ID: 15604294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
